This PDF file includes:

• table S1. Clinical information of tumors.
• table S2. PCR primers for ChIP-PCR and reChIP-PCR.
• table S3. PCR primers for CATCH chromosome capture.
• Legends for tables S4 to S6
• table S7. Summaries of patient cohorts.
• fig. S1. Progestin is a genomic agonist of estrogen-regulated gene expression.
• fig. S2. Progestin is a phenotypic antagonist of estrogen-induced cell proliferation, invasion, and migration.
• fig. S3. Progestin modulates estrogen-regulated gene expression.
• fig. S4. PR redirects ER to sites enriched for motifs of PR and PR-associated cofactors.
• fig. S5. Noncompetitive interactions between ER and PR.
• fig. S6. Depletion of FOXA1 or NF1C insignificantly impacts the effects of PR on ER-regulated gene expression.
• fig. S7. PR-regulated genes are enriched for breast cancer signatures, and PR contributes to the prognostic value of ER.

Download PDF

Other Supplementary Material for this manuscript includes the following:

• table S4 (Microsoft Excel format). Gene expression changes observed in eight ER⁺/PR⁺ patient tumors and three ER+/PR+ cell models in response to various combinations of estrogen and progestin treatments.
• table S5 (Microsoft Excel format). Gene expression changes observed in four ER⁺/PR? patient tumors and two ER+/PR-deficient cell models in response to various combinations of estrogen and progestin treatments.
• table S6 (Microsoft Excel format). Binding sites for ER, PR, and ER/PR complexes in ER⁺/PR⁺ T47D and ER⁺/PR-deficient T47D cells.